Street Calls of the Week
Strata Skin Sciences, Inc. (NASDAQ:SSKN) filed a prospectus supplement on Thursday in connection with its existing equity distribution agreement with Ladenburg Thalmann & Co. Inc. The agreement allows the company to offer and sell up to $11 million in shares of its common stock through registered at-the-market offerings.
The shares are registered under a registration statement on Form S-3 (File No. 333-283418), which was initially filed with the Securities and Exchange Commission on November 22, 2024, and declared effective on December 18, 2024. The prospectus supplement, dated September 26, 2025, enables Strata Skin Sciences to offer and sell shares as needed in the future under the terms of the equity distribution agreement. Despite recent market challenges, the stock has shown resilience with a 15.6% return over the past week.
In connection with the filing, Strata Skin Sciences also submitted an opinion and consent from its counsel, Stevens & Lee, P.C., regarding the legality of the shares being offered. The company emphasized that the current report does not constitute an offer to sell or a solicitation of an offer to buy the securities in any jurisdiction where such actions would be unlawful.
This information is based on a press release statement and the company’s filing with the Securities and Exchange Commission.
In other recent news, Strata Skin Sciences has received an extension from the Nasdaq Stock Market to meet the minimum stockholders’ equity requirement for continued listing. The company now has until February 16, 2026, to comply with the $2.5 million equity threshold. In addition, Strata Skin Sciences has completed a registered direct offering, raising approximately $2.42 million in gross proceeds. This offering involved the sale of over one million shares, facilitated by Ladenburg Thalmann & Co. Inc.
Moreover, the company is highlighting the efficacy of its XTRAC Excimer Laser for treating atopic dermatitis, with expanded indications now allowing broader insurance reimbursements. A recent study has also shown promising results for the laser’s use in vitiligo treatment, demonstrating higher repigmentation rates when combined with JAK inhibitors. Furthermore, clinics using Strata’s Elevate 360 consulting services have reported business growth, showcasing the platform’s potential in optimizing clinic operations. These developments reflect Strata Skin Sciences’ ongoing efforts to strengthen its market position and enhance its offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.